Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks

Radha M. Golla, Min Li, Yulei Shen, Ming Ji, Ying Yan, Kai Fu, Timothy Charles Greiner, Timothy W. Mckeithan, Wing C. Chan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

There is a high incidence of genomic aberration of ataxia telangiectasia mutated (ATM) and genes encoding proteins involved in the ATM pathway in mantle cell lymphoma (MCL). It has been shown that poly(ADP-ribose) polymerase inhibitor (PARPi) strongly enhances the cytotoxicity of agents, causing single-strand DNA breaks in cells with impaired homologous recombination repair. Here, we show that PARPi AG14361 potentiates the cytotoxicity induced by topotecan treatment in MCL cell lines, which was not dependent on either TP53 or CHEK2 status. Inhibition and/or knockdown of ATM and BRCA2 did not potentiate the cytotoxic effect of treatment with PARPi and topotecan. With loss of function of ATM, other kinases can still mediate activation of ATM substrates as demonstrated by continued phosphorylation of CHEK2 (Thr-68), although attenuated and delayed. These results suggest that PARPi may enhance the therapeutic efficacy of DNA damaging agents on MCL through TP53-independent mechanisms without requiring the inhibition of either ATM or BRCA2.

Original languageEnglish (US)
Pages (from-to)175-179
Number of pages5
JournalHematological Oncology
Volume30
Issue number4
DOIs
StatePublished - Dec 1 2012

Fingerprint

Mantle-Cell Lymphoma
Ataxia Telangiectasia
DNA Breaks
Poly(ADP-ribose) Polymerases
Topotecan
Recombinational DNA Repair
Single-Stranded DNA Breaks
Phosphotransferases
Phosphorylation
Cell Line
Poly(ADP-ribose) Polymerase Inhibitors
DNA
Incidence
Proteins

Keywords

  • ATM
  • Mantle cell lymphoma
  • PARP inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks. / Golla, Radha M.; Li, Min; Shen, Yulei; Ji, Ming; Yan, Ying; Fu, Kai; Greiner, Timothy Charles; Mckeithan, Timothy W.; Chan, Wing C.

In: Hematological Oncology, Vol. 30, No. 4, 01.12.2012, p. 175-179.

Research output: Contribution to journalArticle

@article{3e8e40843d544d5cbeaf1a1d0191f966,
title = "Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks",
abstract = "There is a high incidence of genomic aberration of ataxia telangiectasia mutated (ATM) and genes encoding proteins involved in the ATM pathway in mantle cell lymphoma (MCL). It has been shown that poly(ADP-ribose) polymerase inhibitor (PARPi) strongly enhances the cytotoxicity of agents, causing single-strand DNA breaks in cells with impaired homologous recombination repair. Here, we show that PARPi AG14361 potentiates the cytotoxicity induced by topotecan treatment in MCL cell lines, which was not dependent on either TP53 or CHEK2 status. Inhibition and/or knockdown of ATM and BRCA2 did not potentiate the cytotoxic effect of treatment with PARPi and topotecan. With loss of function of ATM, other kinases can still mediate activation of ATM substrates as demonstrated by continued phosphorylation of CHEK2 (Thr-68), although attenuated and delayed. These results suggest that PARPi may enhance the therapeutic efficacy of DNA damaging agents on MCL through TP53-independent mechanisms without requiring the inhibition of either ATM or BRCA2.",
keywords = "ATM, Mantle cell lymphoma, PARP inhibitor",
author = "Golla, {Radha M.} and Min Li and Yulei Shen and Ming Ji and Ying Yan and Kai Fu and Greiner, {Timothy Charles} and Mckeithan, {Timothy W.} and Chan, {Wing C.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1002/hon.1020",
language = "English (US)",
volume = "30",
pages = "175--179",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks

AU - Golla, Radha M.

AU - Li, Min

AU - Shen, Yulei

AU - Ji, Ming

AU - Yan, Ying

AU - Fu, Kai

AU - Greiner, Timothy Charles

AU - Mckeithan, Timothy W.

AU - Chan, Wing C.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - There is a high incidence of genomic aberration of ataxia telangiectasia mutated (ATM) and genes encoding proteins involved in the ATM pathway in mantle cell lymphoma (MCL). It has been shown that poly(ADP-ribose) polymerase inhibitor (PARPi) strongly enhances the cytotoxicity of agents, causing single-strand DNA breaks in cells with impaired homologous recombination repair. Here, we show that PARPi AG14361 potentiates the cytotoxicity induced by topotecan treatment in MCL cell lines, which was not dependent on either TP53 or CHEK2 status. Inhibition and/or knockdown of ATM and BRCA2 did not potentiate the cytotoxic effect of treatment with PARPi and topotecan. With loss of function of ATM, other kinases can still mediate activation of ATM substrates as demonstrated by continued phosphorylation of CHEK2 (Thr-68), although attenuated and delayed. These results suggest that PARPi may enhance the therapeutic efficacy of DNA damaging agents on MCL through TP53-independent mechanisms without requiring the inhibition of either ATM or BRCA2.

AB - There is a high incidence of genomic aberration of ataxia telangiectasia mutated (ATM) and genes encoding proteins involved in the ATM pathway in mantle cell lymphoma (MCL). It has been shown that poly(ADP-ribose) polymerase inhibitor (PARPi) strongly enhances the cytotoxicity of agents, causing single-strand DNA breaks in cells with impaired homologous recombination repair. Here, we show that PARPi AG14361 potentiates the cytotoxicity induced by topotecan treatment in MCL cell lines, which was not dependent on either TP53 or CHEK2 status. Inhibition and/or knockdown of ATM and BRCA2 did not potentiate the cytotoxic effect of treatment with PARPi and topotecan. With loss of function of ATM, other kinases can still mediate activation of ATM substrates as demonstrated by continued phosphorylation of CHEK2 (Thr-68), although attenuated and delayed. These results suggest that PARPi may enhance the therapeutic efficacy of DNA damaging agents on MCL through TP53-independent mechanisms without requiring the inhibition of either ATM or BRCA2.

KW - ATM

KW - Mantle cell lymphoma

KW - PARP inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84870921108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870921108&partnerID=8YFLogxK

U2 - 10.1002/hon.1020

DO - 10.1002/hon.1020

M3 - Article

VL - 30

SP - 175

EP - 179

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 4

ER -